Buy Retatrutide Online

Home > Products > Retatrutide

Buy Retatrutide_500x500px

Retatrutide is a synthetic peptide designed to activate GIP, GLP-1, and glucagon receptors. It is currently being studied in clinical trials for its ability to improve blood glucose control and promote significant weight loss in patients with type 2 diabetes and obesity.

Early research also suggests potential benefits for metabolic health, including reductions in cardiovascular risk factors, though further studies are needed to confirm these effects.

Retatrutide remains under investigation, with promising preliminary results but no definitive conclusions on its full range of therapeutic benefits.

Availability: In-Stock

Price: $99.99

Buy Now

POLARIS PEPTIDES

  • Free Shipping when you spend $350 or more
  • Save an extra 10% when you subscribe to their marketing
  • Spend $500 to also get a free vial from their  'Other Peptides' category’
PinClipart.com_usa-flag-clip-art_5738665
Table Of Contents
    Add a header to begin generating the table of contents

    What is Retatrutide?

    Retatrutide, a synthetic peptide formulated by Eli Lilly, is also known as LY3437943. It consists of 39 amino acids and works by activating three receptors: GLP-1, GIP, and glucagon (GCG) [1]. Both GLP-1 and GIP belong to the incretin family of hormones that boost insulin secretion and influence immune responses. Activation of the GCG receptor is thought to enhance metabolic activity and stimulate energy use [2].

    This novel compound is under investigation for its effectiveness in managing blood sugar and encouraging weight loss [3].

    How Does Retatrutide Work?

    Retatrutide operates by targeting GIP, GLP-1, and GCG receptors, with a significant emphasis on GIP receptor stimulation [4]. Incretin hormones like GLP-1 and GIP help in boosting insulin release from pancreatic beta cells and play a role in creating feelings of satiety. Glucagon counteracts low blood sugar by raising glucose levels during fasting. By engaging these receptors, retatrutide has a comprehensive effect on metabolic regulation, with notable impacts on both glucose control and body weight.

    The peptide primarily acts by strongly activating the GIP receptor, which is pivotal for appetite regulation by affecting the brain’s centers responsible for fullness. This action helps reduce hunger, cravings, and food consumption [8].

    Additionally, the GLP-1 receptor activation aids in controlling blood sugar and heightening satiety. GLP-1 further slows gastric emptying, leading to prolonged feelings of fullness post-meal [9, 10].

    Through the stimulation of GCG receptors, retatrutide is believed to increase energy usage and support fat oxidation, particularly through liver metabolism. It may also induce the conversion of white fat to beige fat, increasing thermogenesis and boosting caloric expenditure [11].

    These actions make retatrutide a promising candidate for research in obesity and type 2 diabetes management by not only limiting calorie intake but also enhancing energy use, offering a dual approach to effective weight management. 

    To explore its potential in further studies, buy retatrutide from our top rated vendor here. 

    peptaides-3

    Retatrutide Benefits | Clinical Trials

    Key findings from various clinical trials, provided below, have demonstrated the potential of retatrutide in several areas

    Retatrutide and Weight Loss Research

    As of 2024, phase 3 studies are underway under the TRIUMPH program, which is investigating retatrutide’s role in weight loss. Earlier phases have already shown encouraging outcomes, with data indicating up to a 24% reduction in baseline weight.

    A 2019 proof-of-concept study in Singapore served as the first human trial for retatrutide. This phase 1 trial included 47 individuals who received weekly doses ranging from 0.1 mg to 6 mg. The trial suggested positive effects on appetite and food consumption, along with favorable safety metrics [4].

    Subsequent research, a larger 48-week phase 2 trial involving 338 overweight and obese participants, demonstrated that higher doses of retatrutide resulted in greater weight loss and improvements in cardiometabolic risk markers. The findings were as follows:

    • 8.7% weight reduction at 1 mg dose
    • 17.1% reduction at 4 mg
    • 22.8% reduction at 8 mg
    • 24.2% reduction at 12 mg
    • 2.1% reduction in the placebo group

    All participants who received either 8 mg or 12 mg weekly saw at least a 5% reduction in initial body weight. Additionally, waist circumference, blood pressure, and lipid profiles improved, along with reductions in fasting glucose and insulin levels, except for HDL cholesterol. 

    Retatrutide and Type 2 Diabetes Research

    Eli Lilly continues to explore the potential of retatrutide in managing both obesity and blood glucose levels in patients with type 2 diabetes. Ongoing research includes phase 3 trials as part of the broader TRIUMPH program, which evaluates the drug’s efficacy in glycemic control and weight loss.

    Earlier clinical trials have already delivered promising results. For instance, a phase 1b study lasting 12 weeks involved 72 adults aged between 20 and 70 years with type 2 diabetes and A1c levels ranging from 7.0% to 10.5%. The participants were treated with either retatrutide, dulaglutide (a GLP-1 agonist already approved by the FDA), or a placebo.

    By the 12th week, those who received the highest retatrutide dose (12 mg weekly) experienced significant reductions in both A1c (up to 1.6%) and weight, with an average loss of 19.7 pounds (8.96 kg). These outcomes were notably better than those observed in the dulaglutide and placebo groups [12].

    Another phase 2 study, which spanned 36 weeks and involved 281 patients with type 2 diabetes, tested retatrutide doses of up to 12 mg per week. Key results included:

    • HbA1c reduction of 2.02% after 24 weeks (compared to minimal change in the placebo group)
    • HbA1c further decreased to 2.16% by week 36
    • Weight loss was dose-dependent, with participants in the 12 mg group losing an average of 16.94% of their body weight
    • Improved lipid profiles, particularly reductions in triglycerides and non-HDL cholesterol, were also noted [6]

    These findings highlight retatrutide’s promising potential in managing both type 2 diabetes and obesity. As ongoing trials continue to shed light on its full therapeutic capabilities, including long-term benefits and risks, those interested in furthering research independently should ensure they buy retatrutide exclusively from verified suppliers to guarantee both accuracy and safety.

    Buy Retatrutide from our top-rated vendor...

    Buy Now!
    peptides-logo

    Side Effects of Retatrutide

    While phase 2 trials indicate that retatrutide generally exhibits a safety profile similar to other GLP-1/GIP peptide analogs, some side effects were observed. Gastrointestinal issues were the most frequently reported adverse events, particularly among participants receiving higher doses.

    In one study of 338 non-diabetic individuals, the most common side effects experienced by those taking the maximum dose of 12 mg weekly included:

    • Nausea: 45%
    • Vomiting: 19%
    • Constipation: 16%
    • Diarrhea: 15%
    • Fatigue: 10%
    • Cardiac arrhythmia: 11%
    • Increased lipase levels: 8%
    • Hepatic disorders: 3%
    • Pancreatitis: 2% (1 participant)

    These gastrointestinal side effects were often the cause of treatment discontinuation. Dropout rates due to adverse events varied from 6% to 16%, depending on the dose administered. Meanwhile, no treatment-related dropouts were recorded in the placebo group [7].

    Though the occurrence of serious side effects was low and comparable to placebo, researchers should be aware of the potential for temporary increases in liver enzymes such as ALT (alanine aminotransferase) and asymptomatic increases in amylase and lipase levels. In one case, a participant in the highest dose group developed acute pancreatitis, emphasizing the importance of monitoring liver and pancreatic function during research.

    peptaides-3

    Is Retatrutide Safe?

    Currently, retatrutide has not been approved for clinical use, and its sale is restricted to research applications. It is still undergoing clinical trials as part of the TRIUMPH phase 3 program, with ongoing investigations into its efficacy and safety. Preliminary data from phase 1 and phase 2 trials suggest that retatrutide is generally well-tolerated, with a safety profile similar to approved incretin mimetics like dulaglutide.

    However, researchers should approach retatrutide with caution, ensuring that all handling and experimentation follow strict professional standards. Proper safety protocols are crucial to minimizing risks associated with the compound. To guarantee quality and purity for reliable research outcomes, we strongly advise to buy retatrutide only from verified suppliers.

    Retatrutide Dosing | Research Only

    For researchers studying retatrutide, specific dosing protocols are recommended to enhance safety and optimize results. The dosing regimen usually begins with lower doses to minimize side effects, followed by gradual increases. The following schedule is commonly used:

    • Weeks 1-4: Start with 1 mg per week
    • Weeks 5-8: Increase to 2 mg per week
    • Weeks 9-12: Increase to 4 mg per week
    • Weeks 13-16: Increase to 8 mg per week
    • Week 17+: Full dose of 12 mg per week

    It’s essential that researchers do not exceed the maximum recommended dosage of 12 mg per week. Retatrutide is designed for once-weekly subcutaneous administration, and due to its extended half-life, it can be injected at any time of day, with or without food [6, 7].

    In clinical trials, the preferred injection site has been the abdomen, specifically at least 2 inches (5 cm) away from the belly button, to minimize the risk of bruising, redness, infection, or irritation. Studies have shown that retatrutide can be safely administered over a 48-week period, with a safety profile comparable to that of a placebo and other incretin mimetics [6, 7].

    This long-term dosing approach indicates that retatrutide does not require cycling on and off, and sustained use is crucial for maximizing its therapeutic effects in weight management and metabolic health improvement.

    Where to Buy Retatrutide Online | 2024 Edition

    There are several online suppliers offering retatrutide for research purposes, but not all vendors maintain high standards of quality. Researchers are advised to buy retatrutide from trusted and vetted sources to ensure purity and accurate results in their studies.

    After thoroughly assessing various vendors by obtaining retatrutide, our peptide review team found that the following supplier consistently excels in peptide purity, prompt delivery, and quality customer support.

    Polaris Peptides

    Polaris Peptides is an emerging supplier specializing in high-quality peptides intended solely for research and development by professionals. This vendor offers several key advantages:

    • Purity and Accuracy: Polaris retatrutide is produced with meticulous precision, ensuring a purity level of over 99%.
    • Transparency: Detailed lab results accompany every Polaris peptide for sale, providing you with the assurance of retatrutide’s quality and integrity.
    • Customer Support: Polaris Peptides provides exceptional customer service, offering personalized assistance and fast shipping for a smooth purchasing process.

    Buy Retatrutide from our top-rated vendor...

    Buy Now!
    peptides-logo

    How to Reconstitute Retatrutide

    Retatrutide is typically supplied as a lyophilized powder and must be reconstituted before use in research. To maintain the peptide’s stability and efficacy, bacteriostatic water is recommended for reconstitution. This type of water contains 0.9% benzyl alcohol, which prevents bacterial growth and keeps the peptide stable for up to four weeks when stored at the appropriate temperature (2 to 8°C or 36 to 46°F) in a refrigerator [13].

    If sterile water is used instead, the peptide’s stability decreases significantly, with a shelf life of only 24 hours. Therefore, bacteriostatic water is generally preferred to ensure a longer period of usability.

    Here is a basic protocol to follow for reconstituting retatrutide:

    1. Allow both the retatrutide powder and the bacteriostatic water vials to reach room temperature while avoiding direct exposure to heat or sunlight.
    2. Clean the rubber stoppers of both vials with alcohol swabs to prevent contamination.
    3. Using a sterile syringe, draw air and inject it into the bacteriostatic water vial to facilitate liquid withdrawal.
    4. Withdraw the necessary amount of bacteriostatic water and inject it carefully into the retatrutide vial. Make sure to inject the water along the side of the vial to avoid foam formation.
    5. If available, sonication equipment can be used to speed up the dissolution process; otherwise, allow the powder to dissolve naturally without shaking the vial.
    6. Inspect the solution for clarity, and discard it if any particles or cloudiness are present.

    By adhering to these steps, researchers can ensure that retatrutide is properly reconstituted for their experiments, minimizing the risk of contamination and maintaining the peptide’s stability for extended use. However, this is only effective if researchers buy retatrutide of the highest quality from trusted sources.

    FAQ

    Retatrutide vs. Semaglutide

    Retatrutide is a triple receptor agonist that targets GLP-1, GIP, and GCG receptors, potentially leading to more significant weight loss and enhanced metabolic outcomes due to its comprehensive mechanism of action.

    On the other hand, Semaglutide is a peptide therapy that functions as a GLP-1 receptor agonist, primarily increasing insulin secretion and reducing appetite to aid in weight loss and glucose control. While additional research is necessary, early studies suggest that Retatrutide may outperform Semaglutide in these areas.

    Retatrutide vs. Tirzepatide

    While retatrutide and tirzepatide share some similarities, both being receptor agonists targeting GLP-1 and GIP receptors, there are key differences. Tirzepatide is a dual receptor agonist that has already been approved by the FDA for treating type 2 diabetes, and it is currently under review for potential use in managing obesity [14]. Retatrutide, on the other hand, functions as a triple receptor agonist by also activating the glucagon (GCG) receptor, which plays an essential role in increasing energy expenditure and promoting fat metabolism.

    Though no direct head-to-head trials between tirzepatide and retatrutide have been conducted to date, early evidence suggests that retatrutide may offer more substantial weight reduction and enhanced glycemic control. This superior efficacy could be attributed to retatrutide’s additional ability to increase energy usage through its activation of the glucagon receptor [15].

    Is Retatrutide a Steroid?

    Retatrutide is not classified as a steroid. Rather, it is a peptide composed of 39 amino acids and works by stimulating the GIP, GLP-1, and glucagon receptors found in different tissues throughout the body, including the brain, pancreas, and fat cells.

    This receptor stimulation leads to improved appetite regulation, enhanced metabolism, and better blood sugar control. Retatrutide does not engage with androgen receptors like traditional anabolic steroids do. Instead, it modulates metabolic processes through its unique multi-receptor activity, distinguishing it from steroid compounds.

    As a result, retatrutide represents a novel approach to managing weight loss and blood glucose levels, with ongoing research examining its broader therapeutic potential.

     

    For example, you could update the Retatrutide page by adding my details and linking it to my Reta product page

    Buy Retatrutide Online | Verdict

    Though retatrutide is still in the research phase, it shows significant promise for therapeutic use in the future. Phase 3 clinical trials are currently examining its effectiveness in managing obesity and type 2 diabetes, and early studies have demonstrated notable outcomes in areas such as weight loss, glycemic control, and metabolic improvement.

    Initial research indicates that retatrutide could provide advantages including enhanced blood glucose control, reduced appetite, and increased fat reduction. Moreover, scientists are investigating its potential cardiovascular benefits, which could further elevate its significance as a valuable research compound.

    In conclusion, researchers looking to investigate this peptide’s potential in weight management and other applications further should buy retatrutide in high-quality, research-grade form from trusted sources. Opting for reputable vendors, like our recommended supplier, ensures safe experimentation and the most reliable results.

    References

    1. Jakubowska, A., Roux, C. W. L., & Viljoen, A. (2024). The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. Endocrinology and metabolism (Seoul, Korea), 39(1), 12–22.
    2. https://doi.org/10.3803/EnM.2024.1942
      Folli, F., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A., La Rosa, S., Perego, C., & Higgins, P. B. (2023). Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets. American journal of physiology. Endocrinology and metabolism, 325(5), E595–E609. https://doi.org/10.1152/ajpendo.00236.2023
    3. Naeem, M., Imran, L., & Banatwala, U. E. S. S. (2024). Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. Health science reports, 7(2), e1864. https://doi.org/10.1002/hsr2.1864
    4. Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O'Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., Pirro, V., Wainscott, D. B., Willard, F. S., Abernathy, M., Morford, L., Du, Y., Benson, C., Gimeno, R. E., Haupt, A., & Milicevic, Z. (2022).
      LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell metabolism, 34(9), 1234–1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013
    5. Doggrell S. A. (2023). Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?. Expert opinion on investigational drugs, 32(5), 355–359. https://doi.org/10.1080/13543784.2023.2206560
    6. Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., & Coskun, T. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England), 402(10401), 529–544. https://doi.org/10.1016/S0140-6736(23)01053-X
    7. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., Hartman, M. L., & Retatrutide Phase 2 Obesity Trial Investigators (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
    8. Samms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021). GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders. Diabetes, 70(9), 1938–1944. https://doi.org/10.2337/dbi21-0002
    9. Baggio, L. L., & Drucker, D. J. (2014). Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. The Journal of clinical investigation, 124(10), 4223–4226. https://doi.org/10.1172/JCI78371
    10. Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011). Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Experimental diabetes research, 2011, 279530. https://doi.org/10.1155/2011/279530
    11. Conceição-Furber, E., Coskun, T., Sloop, K. W., & Samms, R. J. (2022). Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?. Frontiers in endocrinology, 13, 868037. https://doi.org/10.3389/fendo.2022.868037
    12. Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D'Alessio, D. A., & Milicevic, Z. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet (London, England), 400(10366), 1869–1881. https://doi.org/10.1016/S0140-6736(22)02033-5
    13. Novak, E., Stubbs, S. S., Sanborn, E. C., & Eustice, R. M. (1972). The tolerance and safety of intravenously administered benzyl alcohol in methylprednisolone sodium succinate formulations in normal human subjects. Toxicology and applied pharmacology, 23(1), 54–61. https://doi.org/10.1016/0041-008x(72)90203-7
    14. Abbasi J. (2023). FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management. JAMA, 330(22), 2143–2144. https://doi.org/10.1001/jama.2023.24539
    15. Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity?. International journal of obesity (2005), 10.1038/s41366-024-01473-y. Advance online publication. https://doi.org/10.1038/s41366-024-01473-y

    Reviews

    There are no reviews yet. Be the first one to write one.